The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese zucker (fatty) rats

Diabetes

Volumn 59, Issue 4, 2010, Pages 1092-1100

  Sato, Nahoko ^a   Kaneko, Masayuki ^a   Tamura, Mitsutaka ^a   Kurumatani, Hajimu ^a  

^a Pharmaceutical Research Laboratories   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; CHOLESTEROL; GLUCOSE; INSULIN; N ACETYL BETA GLUCOSAMINIDASE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CIRCULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DYSLIPIDEMIA; FATTY LIVER; FOOT SOLE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HINDLIMB; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SKIN SURFACE; SKIN TEMPERATURE; SYSTOLIC BLOOD PRESSURE; THERMOGRAPHY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; ZUCKER DIABETIC FATTY RAT;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL; CRYOPROTECTIVE AGENTS; EPOPROSTENOL; HEMOGLOBIN A, GLYCOSYLATED; INSULIN; KIDNEY; LIVER; MALE; METABOLIC SYNDROME X; OBESITY; PANCREAS; RATS; RATS, ZUCKER; SKIN TEMPERATURE; TRIGLYCERIDES;

EID: 77951166668     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1432     Document Type: Article

References (48)

1. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-131
2. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 2000;43:821-835
3. Crettaz M, Prentki M, Zaninetti D, Jeanrenaud B. Insulin resistance in soleus muscle from obese Zucker rats: involvement of several defective sites. Biochem J 1980;186:525-534
4. Dandona P, Aljada A. Advances in diabetes for the millennium: diabetes and the endothelium. Med Genet Med 2004;6(Suppl.):6
5. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006;116:1071-1080
6. Agouni A, Lagrue-Lak-Hal1 AH, Mostefai1 HA, Tesse1 A, Mulder P, Rouet P, Desmoulin F, Heymes C, Martínez MC, Andriantsitohaina1 R. Red wine polyphenols prevent metabolic and cardiovascular alterations associated with obesity in Zucker fatty rats (Fa/Fa). PLoS One 2009;4:e5557
7. Kuhad A, Sachdeva AK, Chopra K. Attenuation of renoinflammatory cascade in experimental model of diabetic nephropathy by sesamol. J Agric Food Chem 2009;57:6123-6128
8. Liang JH, Li YN, Qi JS, Jia XX. Peroxynitrite-induced protein nitration is responsible for renal mitochondrial damage in diabetic rat. J Endocrinol Invest. 11 September 2009 [Epub ahead of print]
9. Kawaguchi M, Koshimura K, Sohmiya M, Murakami Y, Gonda T, Kato Y. Effect of insulin on nitric oxide synthase-like immunostaining of arteries in various organs in Zucker diabetic fatty rats. Eur J Endocrinol 2001;145: 343-349
10. Song D, Kuo KH, Yao R, Hutchings SR, Pang CC. Inducible nitric oxide synthase depresses cardiac contractile function in Zucker diabetic fatty rats. Eur J Pharmacol 2008;579:253-259
11. Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways. Circ Res 2003;93:523-530
12. Niwano K, Arai M, Koitabashi N, Hara S, Watanabe A, Sekiguchi K, Tanaka T, Iso T, Kurabayashi M. Competitive binding of CREB and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:1036-1042
13. Okuda Y, Sone H, Mizutani S, Asano M, Tsurushima Y, Ogawa M, Tada K, Asakura Y, Kawakami Y, Suzuki S, Yamashita K. Acute effect of beraprost sodium on lower limb circulation in patients with non-insulin-dependent diabetes mellitus-evaluation by color Doppler ultrasonography and laser cutaneous blood flowmetry. Prostaglandins 1996;52:375-384
14. Aso Y, Tayama K, Takanashi K, Inukai T, Takemura Y. Changes in skin blood flow in type 2 diabetes induced by prostacyclin: association with ankle brachial index and plasma thrombomodulin levels. Metabolism 2001;50:568-572
15. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992; 19(Suppl.):I110-I115
16. Ionescu E, Sauter JF, Jeanrenaud B. Abnormal oral glucose torelance in genetically obese (fa/fa) rats. Am J Physiol 1985;248:E500-E506
17. Kurtz TW, Morris RC, Pershadsingh HA. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 1989;13(Pt. 2):896-901
18. Virkamäki A, Korsheninnikova E, Seppälä-Lindroos A, Vehkavaara S, Goto T, Halavaara J, Häkkinen AM, Yki-Järvinen H. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 2001;50:2337-2343
19. Korach-André M, Gounarides J, Deacon R, Beil M, Sun D, Gao J, Laurent D. Age and muscle-type modulated role of intramyocellular lipids in the progression of insulin resistance in nondiabetic Zucker rats. Metabolism 2005;54:522-528
20. Teachey MK, Taylor ZC, Maier T, Saengsirisuwan V, Sloniger JA, Jacob S, Klatt MJ, Ptock A, Kraemer K, Hasselwander O, Henriksen EJ. Interactions of conjugated linoleic acid and lipoic acid on insulin action in the obese Zucker rat. Metabolism 2003;52:1167-1174 (Pubitemid 37203491)
21. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001;98:7522-7527
22. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614
23. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003;100:7265-7270
24. Menon RK, Grace AA, Burgoyne W, Fonseca VA, James IM, Dandona P. Muscle blood flow in diabetes mellitus: evidence of abnormality after exercise. Diabetes Care 1992;15:693-695
25. Ding Y, Vaziri ND, Coulson R, Kamanna VS, Roh DD. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab 2000;279:E11-E17
26. Frisbee JC, Delp MD. Vascular function in the metabolic syndrome and the effects on skeletal muscle perfusion: lessons from the obese Zucker rat. Essays Biochem 2006;42:145-161
27. Young ME, Leighton B. Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem J 1998;329:73-79
28. Matsumoto K, Morishita R, Tomita N, Moriguchi A, Yamasaki K, Aoki M, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue. J Endocrinol 2002;175:217-223
29. Yamashita T, Shikata K, Matsuda M, Okada S, Ogawa D, Sugimoto H, Wada J, Makino H. Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats. Diabetes Res Clin Pract 2002;57:149-161
30. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J. Activation of peroxisome proliferator-activated receptor δ induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 2003;100:15924-15929
31. Burkey BF, Dong M, Gagen K, Eckhardt M, Dragonas N, Chen W, Grosenstein P, Argentieri G, de Souza CJ. Effects of pioglitazone on promoting energy storage, not expenditure, in brown adipose tissue of obese fa/fa Zucker rats: comparison to CL 316,243. Metabolism 2000;49: 1301-1308
32. Nishimatsu H, Suzuki E, Takeda R, Takahashi M, Oba S, Kimura K, Nagano T, Hirata Y. Blockade of endogenous proinflammatory cytokines ameliorates endothelial dysfunction in obese Zucker rats. Hypertens Res 2008; 31:737-743
33. Schäfer A, Pfrang J, Neumüller J, Fiedler S, Ertl G, Bauersachs J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 2008;154:1047-1054
34. Fujiwara K, Nagasaka A, Nagata M, Yamamoto K, Imamura S, Oda N, Sawai Y, Hayakawa N, Suzuki A, Itoh M. A stable prostacyclin analogue reduces high serum TNF-alpha levels in diabetic patients. Exp Clin Endocrinol Diabetes 2004;112:390-394
35. Yamada M, Sasaki R, Sato N, Suzuki M, Tamura M, Matsushita T, Kurumatani H. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. Eur J Pharmacol 2002;449:167-176
36. Chatzipanteli K, Rudolph S, Axelrod L. Coordinate control of lipolysis by prostaglandin E2 and prostacyclin in rat adipose tissue. Diabetes 1992;41: 927-935
37. Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH. Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol 2008;214:434-441
38. Fujiwara K, Mochida S, Ohno A, Arai M, Matsui A, Masaki N, Hirata K, Tomiya T, Yamaoka M, Nagoshi S. Use of prostaglandin I2 analog in treatment of massive hepatic necrosis associated with endothelial cell injury and diffuse sinusoidal fibrin deposition. Dig Dis Sci 1995;40:41-47
39. Li Z, Rodríguez-Iturbe B, Ni Z, Shahkarami A, Sepassi L, Vaziri ND. Effect of hereditary obesity on renal expressions of NO synthase, caveolin-1, AKt, guanylate cyclase, and calmodulin. Kidney Int 2005;68:2766-2772
40. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278-281
41. Whaley-Connell A, DeMarco VG, Lastra G, Manrique C, Nistala R, Cooper SA, Westerly B, Hayden MR, Wiedmeyer C, Wei Y, Sowers JR. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol 2008;28:67-75
42. Watanabe M, Nakashima H, Mochizuki S, Abe Y, Ishimura A, Ito K, Fukushima T, Miyake K, Ogahara S, Saito T. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I2 analog, beraprost sodium. Am J Nephrol 2009;30:1-11
43. Kushiro M, Shikata K, Sugimoto H, Shikata Y, Miyatake N, Wada J, Miyasaka M, Makino H. Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidney Int 1998;53:1314-1320
44. Barit D, Cooper M E. Diabetic patients and kidney protection: an attainable target. J Hypertens 2008;26:S3-S7
45. Siddiqui AH, Ali Q, Hussain T. Protective role of angiotensin II subtype 2 receptor in blood pressure increase in obese Zucker rats. Hypertension 2009;53:256-261
46. Zhao X, Li LY. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008;28:598-606
47. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001;50:1863-1871
48. Riddle MC, Schneider J, Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:1052-1057